{"config":{"lang":["en"],"separator":"[\\s\\-]+","pipeline":["stopWordFilter"]},"docs":[{"location":"","title":"Medical Reference Wiki","text":"<p>Welcome to the clinical reference guide for healthcare professionals.</p>"},{"location":"#how-to-use-this-wiki","title":"How to Use This Wiki","text":"<ul> <li>Use the search function to find specific conditions</li> <li>Click on disease names to see detailed information</li> <li>Follow treatment algorithms and diagnostic flowcharts</li> <li>Check references for latest guidelines</li> </ul>"},{"location":"#contributing","title":"Contributing","text":"<p>To add or update content: 1. Navigate to the relevant file 2. Click the pencil icon to edit 3. Make your changes 4. Add a commit message describing changes 5. Click \"Commit changes\"</p> <p>The site will automatically update within 2-3 minutes.</p>"},{"location":"copd/","title":"Chronic Obstructive Pulmonary Disease (COPD)","text":""},{"location":"copd/#overview","title":"Overview","text":"<p>COPD is a preventable and treatable disease characterized by persistent respiratory symptoms and airflow limitation due to airway and/or alveolar abnormalities, usually caused by significant exposure to noxious particles or gases.</p>"},{"location":"copd/#key-information","title":"Key Information","text":"<ul> <li>ICD-10 Code: J44.1 (COPD with acute exacerbation), J44.0 (COPD with acute lower respiratory infection)</li> <li>Prevalence: ~16 million diagnosed in US, estimated 30 million affected</li> <li>Age of Onset: Typically &gt;40 years with 20+ pack-year smoking history</li> <li>Leading Cause: Tobacco smoke (85-90% of cases)</li> </ul>"},{"location":"copd/#pathophysiology","title":"Pathophysiology","text":"<ul> <li>Chronic Bronchitis: Mucus hypersecretion, airway inflammation</li> <li>Emphysema: Alveolar destruction, loss of elastic recoil</li> <li>Small Airway Disease: Airway narrowing, increased resistance</li> <li>Systemic Inflammation: Cardiovascular and musculoskeletal effects</li> </ul>"},{"location":"copd/#clinical-presentation","title":"Clinical Presentation","text":""},{"location":"copd/#symptoms","title":"Symptoms","text":"<ul> <li>Progressive dyspnea: Initially on exertion, eventually at rest</li> <li>Chronic cough: Often productive, worse in mornings</li> <li>Sputum production: Clear to purulent</li> <li>Wheezing: Especially during exacerbations</li> <li>Chest tightness</li> <li>Fatigue and weakness</li> <li>Weight loss (advanced disease)</li> </ul>"},{"location":"copd/#physical-findings","title":"Physical Findings","text":"<ul> <li>Inspection: Barrel chest, pursed-lip breathing, use of accessory muscles</li> <li>Palpation: Decreased tactile fremitus</li> <li>Percussion: Hyperresonance, decreased diaphragmatic excursion</li> <li>Auscultation: Decreased breath sounds, prolonged expiration, wheezes, rhonchi</li> </ul>"},{"location":"copd/#diagnostic-evaluation","title":"Diagnostic Evaluation","text":""},{"location":"copd/#spirometry-essential-for-diagnosis","title":"Spirometry (Essential for Diagnosis)","text":"<pre><code>graph TD\n    A[Clinical Suspicion of COPD] --&gt; B[Post-bronchodilator Spirometry]\n    B --&gt; C{FEV1/FVC Ratio}\n    C --&gt;|\u22650.70| D[Normal - Consider Other Diagnoses]\n    C --&gt;|&lt;0.70| E[COPD Confirmed]\n\n    E --&gt; F{FEV1 % Predicted}\n    F --&gt;|\u226580%| G[GOLD 1 - Mild]\n    F --&gt;|50-79%| H[GOLD 2 - Moderate]\n    F --&gt;|30-49%| I[GOLD 3 - Severe]\n    F --&gt;|&lt;30%| J[GOLD 4 - Very Severe]</code></pre>"},{"location":"copd/#additional-testing","title":"Additional Testing","text":"<ul> <li>Chest X-ray: Rule out other pathology, assess hyperinflation</li> <li>CT Chest: If surgical evaluation needed, assess emphysema distribution</li> <li>Arterial Blood Gas: If severe disease or acute exacerbation</li> <li>Alpha-1 Antitrypsin Level: If early onset or family history</li> <li>6-Minute Walk Test: Assess functional capacity</li> </ul>"},{"location":"copd/#copd-assessment-test-cat","title":"COPD Assessment Test (CAT)","text":"<ul> <li>Standardized questionnaire (0-40 points)</li> <li>Assesses impact on daily life</li> <li>&lt;10: Low impact, 10-20: Medium impact, 21-30: High impact, &gt;30: Very high impact</li> </ul>"},{"location":"copd/#treatment-algorithm","title":"Treatment Algorithm","text":"<pre><code>graph TD\n    A[Confirmed COPD] --&gt; B[All Patients: Smoking Cessation&lt;br/&gt;Vaccinations, Pulmonary Rehab]\n    B --&gt; C{Symptoms/Exacerbation Risk}\n\n    C --&gt;|Group A&lt;br/&gt;Low symptoms&lt;br/&gt;Low risk| D[Bronchodilator PRN&lt;br/&gt;SABA or SAMA]\n    C --&gt;|Group B&lt;br/&gt;High symptoms&lt;br/&gt;Low risk| E[Long-acting Bronchodilator&lt;br/&gt;LABA or LAMA]\n    C --&gt;|Group C&lt;br/&gt;Low symptoms&lt;br/&gt;High risk| F[LAMA]\n    C --&gt;|Group D&lt;br/&gt;High symptoms&lt;br/&gt;High risk| G[LAMA + LABA]\n\n    E --&gt; H{Adequate Response?}\n    F --&gt; I{Adequate Response?}\n    G --&gt; J{Adequate Response?}\n\n    H --&gt;|No| K[Add LAMA]\n    I --&gt;|No| L[Add LABA]\n    J --&gt;|No| M{Eosinophils \u2265300?}\n\n    M --&gt;|Yes| N[Add ICS]\n    M --&gt;|No| O[Consider Roflumilast&lt;br/&gt;or Azithromycin]</code></pre>"},{"location":"copd/#management","title":"Management","text":""},{"location":"copd/#non-pharmacological-management","title":"Non-Pharmacological Management","text":""},{"location":"copd/#smoking-cessation-most-important","title":"Smoking Cessation (Most Important)","text":"<ul> <li>Counseling: Brief intervention at every visit</li> <li>Pharmacotherapy:</li> <li>Nicotine replacement therapy</li> <li>Bupropion: 150mg twice daily</li> <li>Varenicline: 0.5mg daily \u00d7 3 days, then 0.5mg twice daily \u00d7 4 days, then 1mg twice daily</li> <li>Behavioral Support: Quitlines, support groups</li> </ul>"},{"location":"copd/#pulmonary-rehabilitation","title":"Pulmonary Rehabilitation","text":"<ul> <li>Exercise Training: Aerobic and strength training</li> <li>Education: Disease management, inhaler technique</li> <li>Nutritional Counseling</li> <li>Psychosocial Support</li> <li>Duration: 6-8 weeks minimum</li> </ul>"},{"location":"copd/#vaccinations","title":"Vaccinations","text":"<ul> <li>Influenza: Annual vaccination</li> <li>Pneumococcal: PPSV23 and PCV13 per guidelines</li> <li>COVID-19: Per current recommendations</li> </ul>"},{"location":"copd/#pharmacological-management","title":"Pharmacological Management","text":""},{"location":"copd/#short-acting-bronchodilators-rescue","title":"Short-Acting Bronchodilators (Rescue)","text":"<ul> <li>SABA: Albuterol 2-4 puffs every 4-6 hours PRN</li> <li>SAMA: Ipratropium 2-4 puffs every 6 hours PRN</li> </ul>"},{"location":"copd/#long-acting-bronchodilators","title":"Long-Acting Bronchodilators","text":"<p>LABA (Long-Acting Beta Agonists) - Formoterol: 12 mcg twice daily - Salmeterol: 50 mcg twice daily - Indacaterol: 75 mcg daily</p> <p>LAMA (Long-Acting Muscarinic Antagonists) - Tiotropium: 18 mcg daily - Umeclidinium: 62.5 mcg daily - Glycopyrronium: 50 mcg daily</p> <p>Combination LABA/LAMA - Formoterol/Glycopyrronium (Bevespi) - Vilanterol/Umeclidinium (Anoro)</p>"},{"location":"copd/#inhaled-corticosteroids-ics","title":"Inhaled Corticosteroids (ICS)","text":"<ul> <li>Indications: Eosinophils \u2265300, history of asthma, frequent exacerbations</li> <li>Agents: Fluticasone, Budesonide</li> <li>Combinations: ICS/LABA, Triple therapy (ICS/LABA/LAMA)</li> </ul>"},{"location":"copd/#other-medications","title":"Other Medications","text":"<ul> <li>Roflumilast: 500 mcg daily (severe COPD with chronic bronchitis)</li> <li>Azithromycin: 250 mg daily or 500 mg three times weekly (prevent exacerbations)</li> <li>Oxygen Therapy: If resting SpO2 \u226488% or PaO2 \u226455 mmHg</li> </ul>"},{"location":"copd/#oxygen-therapy","title":"Oxygen Therapy","text":"<ul> <li>Continuous: 15+ hours daily if resting hypoxemia</li> <li>Nocturnal: If sleep-related hypoxemia</li> <li>Exertional: If significant desaturation with activity</li> <li>Target: Maintain SpO2 88-92%</li> </ul>"},{"location":"copd/#exacerbation-management","title":"Exacerbation Management","text":""},{"location":"copd/#assessment-of-severity","title":"Assessment of Severity","text":"<pre><code>graph TD\n    A[COPD Exacerbation] --&gt; B{Severity Assessment}\n    B --&gt;|Mild| C[Increased symptoms&lt;br/&gt;No change in medications]\n    B --&gt;|Moderate| D[Increased symptoms&lt;br/&gt;Requires medication change]\n    B --&gt;|Severe| E[Requires hospitalization&lt;br/&gt;or ED visit]\n\n    C --&gt; F[Increase bronchodilator frequency&lt;br/&gt;Monitor closely]\n    D --&gt; G[Antibiotics if purulent sputum&lt;br/&gt;Oral corticosteroids&lt;br/&gt;Increase bronchodilators]\n    E --&gt; H[Hospital management&lt;br/&gt;IV/Oral steroids&lt;br/&gt;Antibiotics&lt;br/&gt;Oxygen&lt;br/&gt;Consider NIV]</code></pre>"},{"location":"copd/#treatment","title":"Treatment","text":"<ul> <li>Bronchodilators: Increase frequency, add ipratropium/albuterol combination</li> <li>Corticosteroids: Prednisone 40mg daily \u00d7 5 days</li> <li>Antibiotics: If purulent sputum or increased dyspnea</li> <li>Azithromycin, doxycycline, amoxicillin-clavulanate</li> <li>Oxygen: Maintain SpO2 88-92%</li> </ul>"},{"location":"copd/#hospitalization-criteria","title":"Hospitalization Criteria","text":"<ul> <li>Severe symptoms unresponsive to outpatient treatment</li> <li>New or worsening hypoxemia</li> <li>New or worsening hypercapnia</li> <li>Hemodynamic instability</li> <li>Inability to manage at home</li> </ul>"},{"location":"copd/#complications","title":"Complications","text":""},{"location":"copd/#respiratory","title":"Respiratory","text":"<ul> <li>Acute respiratory failure: Hypoxemic or hypercapnic</li> <li>Pneumonia: Increased susceptibility</li> <li>Pneumothorax: Especially with emphysema</li> <li>Pulmonary hypertension: Right heart strain</li> </ul>"},{"location":"copd/#cardiovascular","title":"Cardiovascular","text":"<ul> <li>Cor pulmonale: Right-sided heart failure</li> <li>Arrhythmias: Atrial fibrillation, ventricular arrhythmias</li> <li>Increased MI risk: Systemic inflammation</li> </ul>"},{"location":"copd/#systemic","title":"Systemic","text":"<ul> <li>Weight loss/Cachexia: Poor prognosis indicator</li> <li>Osteoporosis: Especially with steroid use</li> <li>Depression/Anxiety: Common comorbidities</li> <li>Sleep disorders: Sleep apnea, hypoventilation</li> </ul>"},{"location":"copd/#prognosis-and-monitoring","title":"Prognosis and Monitoring","text":""},{"location":"copd/#prognostic-factors","title":"Prognostic Factors","text":"<ul> <li>FEV1: Lower values indicate worse prognosis</li> <li>Exacerbation frequency: &gt;2 per year increases mortality</li> <li>Exercise capacity: 6-minute walk distance</li> <li>Comorbidities: Cardiovascular disease, cancer</li> <li>BMI: Both low and high BMI associated with worse outcomes</li> </ul>"},{"location":"copd/#regular-monitoring","title":"Regular Monitoring","text":"<ul> <li>Spirometry: Annually or if symptoms worsen</li> <li>Symptom assessment: CAT score, mMRC dyspnea scale</li> <li>Exacerbation frequency: Track patterns</li> <li>Inhaler technique: Review at each visit</li> <li>Comorbidities: Screen for cardiovascular disease, osteoporosis</li> </ul>"},{"location":"copd/#related-conditions","title":"Related Conditions","text":"<ul> <li>Asthma - Asthma-COPD Overlap (ACO)</li> <li>Heart Failure - Common comorbidity</li> <li>Sleep Apnea - Overlap syndrome</li> <li>Lung Cancer - Shared risk factors</li> <li>Pulmonary Hypertension</li> </ul>"},{"location":"copd/#key-references","title":"Key References","text":"<ul> <li>GOLD 2024 Guidelines</li> <li>ATS/ERS COPD Guidelines</li> <li>TORCH Trial</li> <li>ECLIPSE Study</li> </ul>"},{"location":"copd/#recent-updates","title":"Recent Updates","text":"<ul> <li>2024: Updated GOLD guidelines with revised treatment algorithms</li> <li>2023: New data on triple therapy efficacy</li> <li>2022: Updated vaccination recommendations</li> </ul> <p>Last updated: [Date] by [Physician Name] Next review: [Date]</p>"},{"location":"editing-guide/","title":"How to Edit This Wiki - Simple Guide","text":""},{"location":"editing-guide/#making-changes-to-existing-pages","title":"Making Changes to Existing Pages","text":"<ol> <li>Find the page you want to edit</li> <li>Navigate to the file in the repository</li> <li> <p>Example: <code>docs/diabetes-type-2.md</code></p> </li> <li> <p>Click the pencil icon (top right of file)</p> </li> <li> <p>Make your changes</p> </li> <li>Edit the text directly</li> <li> <p>Use simple formatting (see below)</p> </li> <li> <p>Save your changes</p> </li> <li>Scroll to bottom</li> <li>Add brief description: \"Updated diabetes medication dosages\"</li> <li> <p>Click \"Commit changes\"</p> </li> <li> <p>Wait 2-3 minutes - the website updates automatically</p> </li> </ol>"},{"location":"editing-guide/#adding-new-disease-pages","title":"Adding New Disease Pages","text":"<ol> <li>Go to the diseases folder: <code>docs/diseases/</code></li> <li>Click \"Add file\" \u2192 \"Create new file\"</li> <li>Name it: <code>new-disease-name.md</code></li> <li>Copy structure from existing disease (like diabetes-type-2.md)</li> <li>Fill in the information</li> <li>Commit the file</li> <li>Update the navigation in <code>mkdocs.yml</code> (ask for help with this)</li> </ol>"},{"location":"editing-guide/#simple-formatting","title":"Simple Formatting","text":""},{"location":"editing-guide/#text-formatting","title":"Text Formatting","text":"<ul> <li><code>**Bold text**</code> makes bold text</li> <li><code>*Italic text*</code> makes italic text</li> <li><code>## Large Heading</code> makes a large heading</li> <li><code>### Smaller Heading</code> makes a smaller heading</li> </ul>"},{"location":"editing-guide/#lists","title":"Lists","text":"<pre><code>- First item\n- Second item\n- Third item\n</code></pre>"},{"location":"editing-guide/#links","title":"Links","text":"<ul> <li>To other pages: <code>[Hypertension](hypertension.md)</code></li> <li>To external sites: <code>[PubMed](https://pubmed.ncbi.nlm.nih.gov/)</code></li> </ul>"},{"location":"editing-guide/#simple-flowcharts","title":"Simple Flowcharts","text":"<pre><code>graph TD\n    A[Start] --&gt; B[Next Step]\n    B --&gt; C[Final Step]</code></pre>"},{"location":"editing-guide/#common-mistakes-to-avoid","title":"Common Mistakes to Avoid","text":"<ul> <li>Don't delete the file headers (the stuff at the top)</li> <li>Don't change file names without updating links</li> <li>Test any complex changes in small steps</li> <li>Ask for help with navigation changes</li> </ul>"},{"location":"editing-guide/#need-help","title":"Need Help?","text":"<p>Contact [Your Name] at [Your Email] for any technical issues.</p>"},{"location":"hypertension/","title":"Hypertension (Essential Hypertension)","text":""},{"location":"hypertension/#overview","title":"Overview","text":"<p>Essential hypertension is persistently elevated blood pressure without an identifiable underlying medical cause. It accounts for 90-95% of all hypertension cases.</p>"},{"location":"hypertension/#key-information","title":"Key Information","text":"<ul> <li>ICD-10 Code: I10 (Essential hypertension)</li> <li>Prevalence: ~45% of US adults</li> <li>Age of Onset: Typically develops gradually over years</li> <li>Risk Factors: Age, family history, obesity, high sodium intake, physical inactivity, excessive alcohol</li> </ul>"},{"location":"hypertension/#pathophysiology","title":"Pathophysiology","text":"<ul> <li>Increased peripheral vascular resistance</li> <li>Enhanced sympathetic nervous system activity</li> <li>Abnormal renal sodium handling</li> <li>Endothelial dysfunction</li> <li>Arterial stiffening with age</li> </ul>"},{"location":"hypertension/#clinical-presentation","title":"Clinical Presentation","text":""},{"location":"hypertension/#symptoms","title":"Symptoms","text":"<ul> <li>Often asymptomatic (\"silent killer\")</li> <li>Headaches (typically occipital, morning)</li> <li>Dizziness or lightheadedness</li> <li>Nosebleeds (rare, severe cases)</li> <li>Shortness of breath with exertion</li> <li>Chest pain (if cardiac involvement)</li> </ul>"},{"location":"hypertension/#physical-findings","title":"Physical Findings","text":"<ul> <li>Elevated blood pressure readings</li> <li>Retinal changes (AV nicking, cotton wool spots, papilledema)</li> <li>Left ventricular hypertrophy (PMI displacement)</li> <li>S4 gallop</li> <li>Carotid bruits</li> </ul>"},{"location":"hypertension/#diagnostic-criteria-and-evaluation","title":"Diagnostic Criteria and Evaluation","text":""},{"location":"hypertension/#blood-pressure-classification-2017-ahaacc-guidelines","title":"Blood Pressure Classification (2017 AHA/ACC Guidelines)","text":"<pre><code>graph TD\n    A[Blood Pressure Reading] --&gt; B{Systolic/Diastolic}\n    B --&gt;|&lt;120 and &lt;80| C[Normal]\n    B --&gt;|120-129 and &lt;80| D[Elevated]\n    B --&gt;|130-139 or 80-89| E[Stage 1 HTN]\n    B --&gt;|\u2265140 or \u226590| F[Stage 2 HTN]\n    B --&gt;|&gt;180 or &gt;120| G[Hypertensive Crisis]\n\n    E --&gt; H[Confirm with Home Monitoring]\n    F --&gt; I[Confirm with Home Monitoring]\n    G --&gt; J[Immediate Evaluation]</code></pre>"},{"location":"hypertension/#initial-workup","title":"Initial Workup","text":"<ul> <li>Confirm Diagnosis: Multiple readings, home BP monitoring, 24-hour ambulatory monitoring</li> <li>Laboratory Tests:</li> <li>Basic metabolic panel (electrolytes, creatinine, eGFR)</li> <li>Fasting glucose and HbA1c</li> <li>Lipid profile</li> <li>TSH</li> <li>Urinalysis and urine microalbumin</li> <li>Imaging: ECG, echocardiogram if LVH suspected</li> <li>Assess for Secondary Causes (if indicated)</li> </ul>"},{"location":"hypertension/#treatment-algorithm","title":"Treatment Algorithm","text":"<pre><code>graph TD\n    A[Confirmed Hypertension] --&gt; B{Stage 1 HTN&lt;br/&gt;130-139/80-89}\n    A --&gt; C{Stage 2 HTN&lt;br/&gt;\u2265140/90}\n\n    B --&gt; D{ASCVD Risk \u226510%&lt;br/&gt;or High Risk?}\n    D --&gt;|Yes| E[Lifestyle + Medication]\n    D --&gt;|No| F[Lifestyle Modifications&lt;br/&gt;3-6 months]\n    F --&gt; G{BP Goal Achieved?}\n    G --&gt;|No| E\n    G --&gt;|Yes| H[Continue Lifestyle]\n\n    C --&gt; I[Lifestyle + Medication]\n\n    E --&gt; J[Start ACE-I/ARB or&lt;br/&gt;Thiazide Diuretic]\n    I --&gt; K[Start 2 medications&lt;br/&gt;Different classes]\n\n    J --&gt; L{Goal &lt;130/80?}\n    K --&gt; L\n    L --&gt;|No| M[Add/Adjust Medications]\n    L --&gt;|Yes| N[Continue Current Therapy]\n\n    M --&gt; O[Consider Combination:&lt;br/&gt;ACE-I/ARB + Thiazide + CCB]</code></pre>"},{"location":"hypertension/#management","title":"Management","text":""},{"location":"hypertension/#lifestyle-modifications-first-line-for-all-patients","title":"Lifestyle Modifications (First-line for all patients)","text":"<ul> <li>Weight Loss: 5-20 mmHg reduction per 10kg weight loss</li> <li>DASH Diet: 8-14 mmHg reduction</li> <li>High fruits, vegetables, low-fat dairy</li> <li>Reduced saturated fat and total fat</li> <li>Sodium Restriction: &lt;2.3g daily (ideal &lt;1.5g) - 2-8 mmHg reduction</li> <li>Physical Activity: 150 min/week moderate exercise - 4-9 mmHg reduction</li> <li>Alcohol Limitation: \u22642 drinks/day men, \u22641 drink/day women - 2-4 mmHg reduction</li> <li>Smoking Cessation: Improves cardiovascular risk</li> </ul>"},{"location":"hypertension/#pharmacological-treatment","title":"Pharmacological Treatment","text":""},{"location":"hypertension/#first-line-agents","title":"First-Line Agents","text":"<ol> <li>ACE Inhibitors</li> <li>Lisinopril: 10-40mg daily</li> <li>Enalapril: 5-20mg twice daily</li> <li> <p>Side effects: Dry cough (10%), hyperkalemia, angioedema</p> </li> <li> <p>Angiotensin Receptor Blockers (ARBs)</p> </li> <li>Losartan: 50-100mg daily</li> <li>Valsartan: 80-320mg daily</li> <li> <p>Preferred if ACE-I intolerant</p> </li> <li> <p>Thiazide/Thiazide-like Diuretics</p> </li> <li>Hydrochlorothiazide: 25-50mg daily</li> <li>Chlorthalidone: 12.5-25mg daily (preferred)</li> <li> <p>Monitor: Electrolytes, kidney function</p> </li> <li> <p>Calcium Channel Blockers</p> </li> <li>Amlodipine: 5-10mg daily</li> <li>Nifedipine XL: 30-90mg daily</li> <li>Side effects: Peripheral edema, gingival hyperplasia</li> </ol>"},{"location":"hypertension/#second-line-agents","title":"Second-Line Agents","text":"<ul> <li>Beta-blockers: Metoprolol, Carvedilol (if heart failure, post-MI)</li> <li>Aldosterone Antagonists: Spironolactone (if resistant HTN)</li> </ul>"},{"location":"hypertension/#target-blood-pressures","title":"Target Blood Pressures","text":"<ul> <li>General Population: &lt;130/80 mmHg</li> <li>Diabetes: &lt;130/80 mmHg</li> <li>CKD: &lt;130/80 mmHg</li> <li>Elderly (&gt;65): &lt;130/80 mmHg if tolerated</li> </ul>"},{"location":"hypertension/#complications","title":"Complications","text":""},{"location":"hypertension/#acute-complications","title":"Acute Complications","text":"<ul> <li>Hypertensive Emergency: BP &gt;180/120 with end-organ damage</li> <li>Hypertensive Urgency: BP &gt;180/120 without end-organ damage</li> </ul>"},{"location":"hypertension/#chronic-complications","title":"Chronic Complications","text":"<ul> <li>Cardiovascular: Coronary artery disease, heart failure, arrhythmias</li> <li>Cerebrovascular: Stroke, transient ischemic attacks</li> <li>Renal: Chronic kidney disease, end-stage renal disease</li> <li>Retinal: Hypertensive retinopathy, vision loss</li> <li>Peripheral Vascular: Peripheral artery disease</li> </ul>"},{"location":"hypertension/#special-populations","title":"Special Populations","text":""},{"location":"hypertension/#pregnancy","title":"Pregnancy","text":"<ul> <li>Chronic HTN: Continue safe medications (methyldopa, labetalol, nifedipine)</li> <li>Gestational HTN: Monitor closely, deliver if severe</li> <li>Preeclampsia: Immediate obstetric consultation</li> </ul>"},{"location":"hypertension/#diabetes","title":"Diabetes","text":"<ul> <li>Preferred agents: ACE-I or ARB (renoprotective)</li> <li>Target: &lt;130/80 mmHg</li> <li>Monitor kidney function closely</li> </ul>"},{"location":"hypertension/#heart-failure","title":"Heart Failure","text":"<ul> <li>Preferred agents: ACE-I/ARB + beta-blocker + diuretic</li> <li>Avoid: Non-dihydropyridine CCBs</li> </ul>"},{"location":"hypertension/#monitoring","title":"Monitoring","text":""},{"location":"hypertension/#follow-up-schedule","title":"Follow-up Schedule","text":"<ul> <li>Initiation: 2-4 weeks after starting/changing medication</li> <li>Stable: Every 3-6 months</li> <li>Uncontrolled: Monthly until goal achieved</li> </ul>"},{"location":"hypertension/#home-blood-pressure-monitoring","title":"Home Blood Pressure Monitoring","text":"<ul> <li>Validated device with appropriate cuff size</li> <li>Take readings same time daily</li> <li>Average multiple readings over 1 week</li> <li>Target: &lt;130/80 mmHg</li> </ul>"},{"location":"hypertension/#laboratory-monitoring","title":"Laboratory Monitoring","text":"<ul> <li>Baseline: Complete metabolic panel</li> <li>Follow-up: Electrolytes and creatinine 2-4 weeks after ACE-I/ARB/diuretic initiation</li> <li>Ongoing: Annual labs if stable</li> </ul>"},{"location":"hypertension/#related-conditions","title":"Related Conditions","text":"<ul> <li>Type 2 Diabetes - Often coexistent</li> <li>Coronary Artery Disease</li> <li>Heart Failure</li> <li>Chronic Kidney Disease</li> <li>Metabolic Syndrome</li> </ul>"},{"location":"hypertension/#key-references","title":"Key References","text":"<ul> <li>2017 AHA/ACC Hypertension Guidelines</li> <li>SPRINT Trial Results</li> <li>JNC 8 Guidelines</li> <li>DASH Diet Information</li> </ul>"},{"location":"hypertension/#recent-updates","title":"Recent Updates","text":"<ul> <li>2024: Updated cardiovascular risk calculators</li> <li>2023: New data on SGLT2 inhibitors in hypertension</li> <li>2022: Revised guidelines for elderly patients</li> </ul>"}]}